AbSci Corporation (ABSI) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News...

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News...

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first...

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative...

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first...

Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day

Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development...